LLY

903

-1.58%↓

JNJ

235.46

-0.93%↓

ABBV

204.23

-0.92%↓

NVS

145.89

-1.52%↓

AZN

183.37

-2.88%↓

LLY

903

-1.58%↓

JNJ

235.46

-0.93%↓

ABBV

204.23

-0.92%↓

NVS

145.89

-1.52%↓

AZN

183.37

-2.88%↓

LLY

903

-1.58%↓

JNJ

235.46

-0.93%↓

ABBV

204.23

-0.92%↓

NVS

145.89

-1.52%↓

AZN

183.37

-2.88%↓

LLY

903

-1.58%↓

JNJ

235.46

-0.93%↓

ABBV

204.23

-0.92%↓

NVS

145.89

-1.52%↓

AZN

183.37

-2.88%↓

LLY

903

-1.58%↓

JNJ

235.46

-0.93%↓

ABBV

204.23

-0.92%↓

NVS

145.89

-1.52%↓

AZN

183.37

-2.88%↓

Home・Akcijų sąrašas・ACADIA Pharmaceuticals Inc

ACADIA Pharmaceuticals Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

20.71 0.34

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

20.58

Max

20.77

Pagrindiniai rodikliai
By Trading Economics
Pajamos	202M 274M
Pardavimai	5.4M 284M
P/E Sektoriaus vid.	9.3 57.833
Pelnas, tenkantis vienai akcijai	0.42
Pelno marža	96.33
Darbuotojai	796
EBITDA	-21M 26M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+56.85% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-05-06

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-537M 3.6B
Ankstesnė atidarymo kaina	20.37
Ankstesnė uždarymo kaina	20.71

Naujienos nuotaikos

By Acuity

20%

80%

32 / 350 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bullish Evidence

14.845 / N/A Palaikymas ir pasipriešinimas

ACADIA Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-03-22 23:50; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-03-22 23:50; UTC

Rinkos pokalbiai

LG Electronics Set to Stage Strong Earnings Rebound in 1Q -- Market Talk

2026-03-22 23:49; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Gold Edges Lower on Prospects of Liquidity-Driven Sales -- Market Talk

2026-03-22 23:49; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Nikkei May Fall as Concerns About Middle East Conflict Persist -- Market Talk

2026-03-22 23:49; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Global Forex and Fixed Income Roundup: Market Talk

2026-03-22 23:41; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Oil Edges Lower as Traders Eye Trump's Deadline to Reopen Strait of Hormuz -- Market Talk

2026-03-22 22:57; UTC

Įsigijimai, susijungimai, perėmimai

Perseus Mining: Location of Aurum's Discoveries Present Potential Future Synergies

2026-03-22 22:56; UTC

Įsigijimai, susijungimai, perėmimai

Perseus Mining: Aurum Share Acquisition Cost A$23.69 Million

2026-03-22 22:56; UTC

Įsigijimai, susijungimai, perėmimai

Perseus Mining: Aurum's Boundiali Gold Project Located to South of Sissingue Gold Mine

2026-03-22 22:55; UTC

Įsigijimai, susijungimai, perėmimai

Perseus Mining: Participated in Aurum Resources Equity Raising

2026-03-22 22:54; UTC

Įsigijimai, susijungimai, perėmimai

Perseus Mining: Acquires 9.9% Interest in Aurum Resources

2026-03-22 22:22; UTC

Rinkos pokalbiai

Svarbiausios naujienos

After Selloff, Gold Seen Supported by Strait of Hormuz Deadline -- Market Talk

2026-03-22 22:06; UTC

Įsigijimai, susijungimai, perėmimai

Synopsys Has Market Value Over $80 Billion; Major Customers Include Nvidia -- WSJ

2026-03-22 22:06; UTC

Įsigijimai, susijungimai, perėmimai

Activist Elliott Builds Big Stake in Chip-Design Software Maker Synopsys -- WSJ

2026-03-22 22:06; UTC

Įsigijimai, susijungimai, perėmimai

Activist Elliott Investment Management Has Multibillion-Dollar Investment in Synopsys, Sources Say -- WSJ

2026-03-22 22:06; UTC

Įsigijimai, susijungimai, perėmimai

Elliott Plans to Push Synopsys to Make More Money From Its Software and Services, Sources Say -- WSJ

2026-03-22 21:53; UTC

Uždarbis

Zijin Gold International Plans 59.2 Tons of Gold Production in 2026; up 12.3% on Year >2259.HK

2026-03-22 21:53; UTC

Uždarbis

Zijin Gold International Rising Gold Prices Supported Results >2259.HK

2026-03-22 21:53; UTC

Uždarbis

Zijin Gold International 2025 Rev $5.38B Vs. $2.99B >2259.HK

2026-03-22 21:53; UTC

Uždarbis

Zijin Gold International 2025 Net $1.60B Vs. Net $481.37M >2259.HK

2026-03-22 21:31; UTC

Uždarbis

China Petroleum & Chemical Plans CNY131.6B-CNY148.6B Capex Spending in 2026>0386.HK

2026-03-22 21:31; UTC

Uždarbis

China Petroleum & Chemical: Decrease in Sales Volumes of Refined Oil Products Also Hurt Results >0386.HK

2026-03-22 21:31; UTC

Uždarbis

China Petroleum & Chemical 2025 Results Weighed by Decrease in Prices of Petroleum, Petrochemical Products>0386.HK

2026-03-22 21:31; UTC

Uždarbis

China Petroleum & Chemical 2025 Rev CNY2.78T Vs. CNY3.07T >0386.HK

2026-03-22 21:31; UTC

Uždarbis

China Petroleum & Chemical 2025 Net CNY32.48B Vs. Net CNY48.94B >0386.HK

2026-03-22 21:25; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Bonds Decoupling From Oil Amid Longer Conflict Fears -- Market Talk

2026-03-22 21:22; UTC

Įsigijimai, susijungimai, perėmimai

St Barbara: Remarks Follow Recent Inquiries About Simberi's Fuel Stocks

2026-03-22 21:21; UTC

Įsigijimai, susijungimai, perėmimai

St Barbara: Simberi Currently Uses About 65,000 Liters Per Day For Mining Fleet, Power Generation

2026-03-22 21:21; UTC

Rinkos pokalbiai

Revised Fuel Subsidy Mechanism Positive for Ampol, Viva Energy -- Market Talk

2026-03-22 21:21; UTC

Įsigijimai, susijungimai, perėmimai

St Barbara: Has Been Taking Precaution to Increase Diesel Storage For Several Months

Akcijų palyginimas

Kainos pokytis

ACADIA Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

56.85% į viršų

12 mėnesių prognozė

Vidutinis 32.53 USD 56.85%

Aukščiausias 40 USD

Žemiausias 23 USD

Remiantis 16 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines ACADIA Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

16 ratings

Pirkti

Laikyti

Parduoti

Remiantis 16 analitikų, pateikusių ACADIA Pharmaceuticals Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

14.845 / N/APalaikymas ir pasipriešinimas

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Rinkos nuotaikos

By Acuity

32 / 350 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę ACADIA Pharmaceuticals Inc

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.